CTSO Quote, Financials, Valuation and Earnings

EXACT Sciences Corp. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of -2.3%. CytoSorbents Corp.'s return on equity of -89.32% beat EXACT Sciences Corp.'s return on equity of -38%.

CytoSorbents Corp. has a consensus price target of $4.92, signalling upside risk potential of 669.19%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.96%. Given that CytoSorbents Corp. has higher upside potential than EXACT Sciences Corp., analysts believe CytoSorbents Corp. is more attractive than EXACT Sciences Corp..

CytoSorbents Corp. has a beta of 1.320, which suggesting that the stock is 31.967% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.404, suggesting its more volatile than the S&P 500 by 40.386%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. CytoSorbents Corp.'s net income of -$3.2M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.14x versus 6.18x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of 13.85%. CytoSorbents Corp.'s return on equity of -89.32% beat Illumina, Inc.'s return on equity of 30.55%.

CytoSorbents Corp. has a consensus price target of $4.92, signalling upside risk potential of 669.19%. On the other hand Illumina, Inc. has an analysts' consensus of $125.28 which suggests that it could fall by -4.49%. Given that CytoSorbents Corp. has higher upside potential than Illumina, Inc., analysts believe CytoSorbents Corp. is more attractive than Illumina, Inc..

CytoSorbents Corp. has a beta of 1.320, which suggesting that the stock is 31.967% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.855%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. CytoSorbents Corp.'s net income of -$3.2M is lower than Illumina, Inc.'s net income of $150M. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 29.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.14x versus 4.82x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Natera, Inc. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of -14.78%. CytoSorbents Corp.'s return on equity of -89.32% beat Natera, Inc.'s return on equity of -26.6%.

CytoSorbents Corp. has a consensus price target of $4.92, signalling upside risk potential of 669.19%. On the other hand Natera, Inc. has an analysts' consensus of $246.26 which suggests that it could grow by 7.5%. Given that CytoSorbents Corp. has higher upside potential than Natera, Inc., analysts believe CytoSorbents Corp. is more attractive than Natera, Inc..

CytoSorbents Corp. has a beta of 1.320, which suggesting that the stock is 31.967% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.620, suggesting its more volatile than the S&P 500 by 61.981%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than Natera, Inc. quarterly revenues of $592.2M. CytoSorbents Corp.'s net income of -$3.2M is higher than Natera, Inc.'s net income of -$87.5M. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.14x versus 14.60x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Star Operating Cos., Inc. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of 14.56%. CytoSorbents Corp.'s return on equity of -89.32% beat Star Operating Cos., Inc.'s return on equity of -3.67%.

CytoSorbents Corp. has a consensus price target of $4.92, signalling upside risk potential of 669.19%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 6.67%. Given that CytoSorbents Corp. has higher upside potential than Star Operating Cos., Inc., analysts believe CytoSorbents Corp. is more attractive than Star Operating Cos., Inc..

CytoSorbents Corp. has a beta of 1.320, which suggesting that the stock is 31.967% more volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.711, suggesting its more volatile than the S&P 500 by 171.052%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than Star Operating Cos., Inc. quarterly revenues of $23.7M. CytoSorbents Corp.'s net income of -$3.2M is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.14x versus 0.54x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.